Even though there has been little research into how ILC2s influence tumorigenesis and/or progression, ILC2s and/or their signature cytokines, such as IL-5 and IL-13, have been shown to be involved in pro- [13,14,15,16,18,38,39,40] and anti-tumor [19,20,21] immune responses. The gene discussed is IL13; the disease is neoplasm.